Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Euronext Paris  -  11:35 2022-08-08 am EDT
1.417 EUR   +1.21%
08/04Novacyt Launches First Fully Lyophilized Direct-to-PCR Assays; Shares Up 5%
MT
08/04Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays
CI
07/28Novacyt Creates Research-use-only Adenovirus F41 Test Kit Amid Rising Hepatitis Cases
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
08/02/2022 08/03/2022 08/04/2022 08/05/2022 08/08/2022 Date
1.34(c) 1.355(c) 1.388(c) 1.4(c) 1.417(c) Last
131 917 658 626 452 552 120 488 166 807 Volume
-2.69% +1.12% +2.44% +0.86% +1.21% Change
More quotes
Estimated financial data (e)
Sales 2020 277 M - -
Net income 2020 132 M - -
Net cash position 2020 89,4 M - -
P/E ratio 2020 5,05x
Yield 2020 -
Sales 2021 95,8 M - -
Net income 2021 -9,73 M - -
Net cash position 2021 99,9 M - -
P/E ratio 2021 -31,3x
Yield 2021 -
Capitalization 100 M 102 M -
EV / Sales 2020 2,17x
EV / Sales 2021 2,19x
Nbr of Employees 276
Free-Float 94,8%
More Financials
Company
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors: - development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular screening kits (Primerdesign): for... 
Read more
More about the company
All news about NOVACYT
08/04Novacyt Launches First Fully Lyophilized Direct-to-PCR Assays; Shares Up 5%
MT
08/04Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-P..
CI
07/28Novacyt Creates Research-use-only Adenovirus F41 Test Kit Amid Rising Hepatitis Cases
MT
07/28Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay
CI
07/21NOVACYT : Results of Annual General Meeting
PU
07/21NOVACYT : AGM Investor Presentation
PU
07/15Novacyt - Approval of exsig COVID-19 Direct test in the UK under CTDA legislation
AQ
07/15UK Watchdog OKs Novacyt's exsig COVID-19 Direct Test
MT
07/15Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK
CI
07/07NOVACYT : Half-year results
CO
06/30NOVACYT : Monthly statement on outstanding equity shares and voting rights
CO
06/28France's Novacyt Rolls Out Monkeypox Assay
MT
06/28Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeyp..
CI
06/21NOVACYT : Mixed general shareholder meeting
CO
06/19NOVACYT : Convening notice for 21st June 2022
PU
More news
News in other languages on NOVACYT
08/04CAC40 : franchit les 6.500 porté par les valeurs bancaires
08/04Novacyt lance les premiers tests Direct-to-PCR entièrement lyophilisés ; les actions so..
08/04CAC40 : s'approche des 6500, porté par les valeurs bancaires
08/04NOVACYT : lancement de nouveaux tests PCR lyophilisés
08/04BOLSA DE MADRID : La tecnología está cansada de ir cuesta abajo
More news
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
David Allmond Chief Executive Officer & Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Paul Oladimeji Group Head-Research & Development
Bryan Close Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-67.65%100
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
MODERNA, INC.-26.44%73 092
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499